type here...

CATEGORIES

Medication

LATEST

1234Page 4 of 4

TRENDING

EDITORS CHOICE

Achieve Life Sciences Announces Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Medika Life -
Clinical results in primary and secondary endpoints for 6- and 12-week experimental smoking cessation treatment reported by company sponsor.

Psilocybin as an Antidepressant for Cancer Patients Who Are Not Depressed

James Coyne -
Research concerning the role of psychedelics in mental health treatment and its superb publicity campaign depends on millions of dollars raised by venture capitalists.

How Dare You Criticize Psychiatrists Who Praise Studies of Psychedelics As Antidepressants?

James Coyne -
All claims about treatments affecting human health and well-being should be subject to robust review. That review requires someone to facilitate criticism, locate qualified critics, and bring them into the discussion.

The Future of Cardiovascular Disease Prevention: Insights from Drs. Eric Topol and Pradeep Natarajan

Christopher Nial -
While LDL cholesterol remains a crucial target in cardiovascular prevention, it is important to look beyond this traditional marker.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories